Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Patent: 9,187,522

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,187,522
Title:GLP-1 receptor modulators
Abstract: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where \"\" represents either or both the R and S form of the compound): ##STR00001## where A, B, C, Y.sub.1, Y.sub.2, Z, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, W.sub.1, n, p and q are as defined herein.
Inventor(s): Boehm; Marcus F. (San Diego, CA), Martinborough; Esther (San Diego, CA), Moorjani; Manisha (San Diego, CA), Tamiya; Junko (Carlsbad, CA), Huang; Liming (San Diego, CA), Yeager; Adam R. (La Mesa, CA), Brahmachary; Enugurthi (San Diego, CA), Fowler; Thomas (Melton Mowbray, GB), Novak; Andrew (Nottingham, GB), Meghani; Premji (Leicestershire, GB), Knaggs; Michael (Burton-on-Trent, GB)
Assignee: Receptos, Inc. (San Diego, CA)
Application Number:14/296,907
Patent Claims:see list of patent claims

Details for Patent 9,187,522

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Llc TANZEUM albiglutide For Injection 125431 2014-04-15 ⤷  Try it Free 2039-02-26
Sanofi-aventis U.s. Llc ADLYXIN lixisenatide Injection 208471 2016-07-27 ⤷  Try it Free 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.